APA (7th ed.) Citation

AP, K., MD, L., J, D., S, K., L, E., GJ, V., . . . CU, N. (2022). Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): Primary analysis of an open-label, randomised, phase 2 trial. The Lancet. Oncology, 23(6), 818. https://doi.org/10.1016/S1470-2045(22)00220-0

Chicago Style (17th ed.) Citation

AP, Kater, et al. "Minimal Residual Disease-guided Stop and Start of Venetoclax Plus Ibrutinib for Patients with Relapsed or Refractory Chronic Lymphocytic Leukaemia (HOVON141/VISION): Primary Analysis of an Open-label, Randomised, Phase 2 Trial." The Lancet. Oncology 23, no. 6 (2022): 818. https://doi.org/10.1016/S1470-2045(22)00220-0.

MLA (9th ed.) Citation

AP, Kater, et al. "Minimal Residual Disease-guided Stop and Start of Venetoclax Plus Ibrutinib for Patients with Relapsed or Refractory Chronic Lymphocytic Leukaemia (HOVON141/VISION): Primary Analysis of an Open-label, Randomised, Phase 2 Trial." The Lancet. Oncology, vol. 23, no. 6, 2022, p. 818, https://doi.org/10.1016/S1470-2045(22)00220-0.